Amgen | AMGN

Stock Price
467.06
Daily Change
-1.05 -0.22%
Monthly
13.13%
Yearly
39.01%
Q4 Forecast
450.57

EPS Reference Time Actual Consensus Previous
2026-11-03 FY2026Q3 PM 6.45 5.76 5.64
2026-08-04 FY2026Q2 PM 6.29 5.59 6.02
2026-04-30 FY2026Q1 PM 5.15 4.79 4.90
2026-02-03 FY2025Q4 PM 5.29 4.72 5.31
2025-11-04 FY2025Q3 PM 5.64 5.07 5.58



Peers Price Chg Day Year Date
Takeda 6,825.00 152.00 2.28% 55.82% Nov/12
AbbVie 294.45 -0.53 -0.18% 26.76% Nov/12
Agios Pharmaceuticals 31.76 -1.06 -3.23% -25.34% Nov/12
ALKERMES 47.47 -0.42 -0.88% 53.08% Nov/12
Amgen 467.06 -1.05 -0.22% 39.01% Nov/12
Biogen 250.48 -2.92 -1.15% 52.05% Nov/12
BioMarin Pharmaceutical 56.70 -1.63 -2.79% 4.57% Nov/12
Bristol-Myers Squibb 62.32 -0.59 -0.94% 28.15% Nov/12
Coherus Biosciences 0.54 -0.04 -7.55% -57.26% Nov/12
Exelixis 69.84 -0.86 -1.22% 64.91% Nov/12

Indexes Price Day Year Date
US Index 500 7618 -26.98 -0.35% 13.07% Nov/12
USND 25366 -106.63 -0.42% 10.91% Nov/12
US Index 30 52405 -189.40 -0.36% 10.43% Nov/12
US Index 100 28423 -85.06 -0.30% 13.72% Nov/12

Amgen traded at $467.06 this Thursday November 12th, decreasing $1.05 or 0.22 percent since the previous trading session. Looking back, over the last four weeks, Amgen lost 13.13 percent. Over the last 12 months, its price rose by 39.01 percent. Looking ahead, we forecast Amgen to be priced at 450.57 by the end of this quarter and at 422.26 in one year, according to Trading Economics global macro models projections and analysts expectations.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.



News Stream
Amgen Shares Hit 5-week High
Amgen shares increased to 426.77 USD, the highest since September 2026. Over the past 4 weeks, Amgen gained 13.36%, and in the last 12 months, it increased 43.22%.
2026-10-14
Amgen Stock Price Hits 4-week Low
Amgen shares decreased to 407.08 USD, the lowest since August 2026. Over the past 4 weeks, Amgen gained 0.05%, and in the last 12 months, it increased 43.85%.
2026-09-08
Amgen Stock Price Hits 11-week High
Amgen shares increased to 358.73 USD, the highest since April 2026. Over the past 4 weeks, Amgen gained 6.78%, and in the last 12 months, it increased 28.52%.
2026-06-25